Literature DB >> 22116092

Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients.

Ihosvany Fernández Bello1, María T Álvarez, Francisco J López-Longo, Elena G Arias-Salgado, Mónica Martín, Víctor Jiménez-Yuste, Ana Rodríguez de la Rúa, Nora V Butta.   

Abstract

Platelets are the major source of plasma-soluble CD40L (sCD40L), an important inflammatory mediator. This study explored the impact of platelet-derived sCD40L on Behçet disease (BD), an autoinflammatory vasculitis. We also searched for influences by platelet matrix metalloproteinases (MMP) -2 and MMP-9, implicated in several inflammatory diseases, on CD40L shedding from platelet membrane. Platelet activation were studied by flow cytometry and aggregometry, surface expression of CD40L and platelet-leukocyte aggregates by flow cytometry, sCD40L by ELISA, cellular CD40L and CD40 levels by Western blot and MMPs activity by gelatin zymography. The effect of sCD40L on MMP9 expression was studied in cultured MEG-01 cells. Plasma and platelet-released sCD40L levels were higher in BD patients. No differences in platelet activation and in platelet-leukocyte aggregates formation were observed between BD patients and controls. Plasma and platelet MMP-9 levels were increased in BD patients, whereas there was no difference in platelet MMP-2 activity. Since a correlation between plasma sCD40L and platelet MMP-9 activity was observed, we studied the influence of sCD40L on MMP-9 levels in the megakaryoblastic cell line MEG-01. Treatment of MEG-01 cells with recombinant sCD40L increased MMP-9 but did not change MMP-2 levels. In conclusion, sCD40L release from platelets was mediated by MMP-9, and MMP-9 expression was in turn upregulated by sCD40L in the MEG-01 cell line. We conclude that platelets and megakaryocytes might participate in a positive feedback loop occurring between sCD40L and MMP-9 which would contribute to the proinflammatory state observed in BD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116092     DOI: 10.1160/TH11-08-0556

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens.

Authors:  L Cantarini; V Pucino; A Vitale; R Talarico; O M Lucherini; F Magnotti; V De Rosa; M Galgani; C Alviggi; G Marone; M Galeazzi; G Matarese
Journal:  Clin Exp Immunol       Date:  2016-02-24       Impact factor: 4.330

Review 2.  Emerging roles for platelets as immune and inflammatory cells.

Authors:  Craig N Morrell; Angela A Aggrey; Lesley M Chapman; Kristina L Modjeski
Journal:  Blood       Date:  2014-02-28       Impact factor: 22.113

3.  Streptococcus sanguinis-induced cytokine and matrix metalloproteinase-1 release from platelets.

Authors:  Fabrice Cognasse; Hind Hamzeh-Cognasse; Adrien Chabert; Elke Jackson; Charles-Antoine Arthaud; Olivier Garraud; Archie McNicol
Journal:  BMC Immunol       Date:  2014-04-22       Impact factor: 3.615

Review 4.  The signaling role of CD40 ligand in platelet biology and in platelet component transfusion.

Authors:  Chaker Aloui; Antoine Prigent; Caroline Sut; Sofiane Tariket; Hind Hamzeh-Cognasse; Bruno Pozzetto; Yolande Richard; Fabrice Cognasse; Sandrine Laradi; Olivier Garraud
Journal:  Int J Mol Sci       Date:  2014-12-03       Impact factor: 5.923

5.  Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity.

Authors:  Ihosvany Fernández-Bello; Francisco J López-Longo; Elena G Arias-Salgado; Víctor Jiménez-Yuste; Nora V Butta
Journal:  Orphanet J Rare Dis       Date:  2013-05-27       Impact factor: 4.123

6.  Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet's disease.

Authors:  Sandro Félix Perazzio; Paulo Vitor Soeiro-Pereira; Viviane Cardoso Dos Santos; Marlon Vilela de Brito; Bruno Salu; Maria Luiza Vilela Oliva; Anne Margherite Stevens; Alexandre Wagner Silva de Souza; Hans D Ochs; Troy R Torgerson; Antonio Condino-Neto; Luis Eduardo Coelho Andrade
Journal:  Arthritis Res Ther       Date:  2017-10-19       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.